Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.86 +2.73%
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +54.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67.41 million.
GUIDANCE:
Reaffirmed 2018 revenue guidance of $250-270 million
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Yeti outlines growth targets and financial framework through 2030
- Astrana Health (ASTH) Mentioned as short at Glass House
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
